Our Take
One company's quick turnaround does not prove domestic manufacturing is faster across the industry; the real question is whether the FDA feedback loop favors makers who can iterate on-site.
Why it matters
Drugmakers are caught between pricing pressure (which favors cheap overseas production) and time-to-market risk (which favors domestic control). Aquestive's case offers a concrete test of that trade-off.
Do this week
Operations leads: map your current FDA feedback cycle for a recent rejection or major amendment, then compare timeline against a peer who manufactures domestically, before budget planning season.
Aquestive's FDA response cycle
Aquestive, a specialty pharmaceutical manufacturer, recovered quickly from an FDA rejection by iterating on its manufacturing process domestically. The company's fast turnaround prompted industry observers to examine whether US-based drug production confers a speed advantage over offshore operations (per PharmaVoice).
The case is narrow but instructive. Aquestive faced regulatory feedback, adjusted operations, and resubmitted within a timeframe that would be harder to achieve if manufacturing were distributed across multiple geographies or if communication with FDA inspectors required longer lead times for site visits and remediation.
The domestic-cost-speed trade-off is real
Pharmaceutical executives have long accepted that US manufacturing costs more. Labor, compliance overhead, and facility standards run higher than in India, China, or Eastern Europe. That math has pushed generic and commodity drug production overseas for decades.
What Aquestive's case surfaces is the hidden cost of that distance: regulatory cycle time. If an FDA inspection uncovers a manufacturing defect or process gap, the remediation loop tightens when the plant is 20 miles from the agency's field office and your engineering team can iterate in days, not weeks. Offshore plants face travel delays, timezone friction, and the need to coordinate changes across multiple legal and operational jurisdictions.
For drugs with competitive pressure or narrow therapeutic windows, that speed can mean market share. For drugs fighting generics, it may not matter enough to justify the 20–40% cost premium of domestic production.
Audit your FDA cycle times by geography
If you manage manufacturing operations or supply chain strategy, pull your last five FDA warning letters or 483 observations and calculate the calendar time from inspection finding to resubmission. Then segment by manufacturing location. You will likely find that domestic plants close the loop faster, but the margin may not justify the cost uplift for your molecule type.
For high-value products with thin patent cliffs or clinical evidence packages that depend on timely approvals, domestic or nearshore production becomes a negotiating lever with FDA and a competitive moat. For volume generics, it almost certainly does not.